Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Trial Profile

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Osteosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Oct 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 19 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top